Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A French Multicentric Observational Study of Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia Patients

NCT05437250 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05437250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05437250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A French Multicentric Observational Study of Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
September 13, 2022
Completion date
November 15, 2026
Enrollment
350 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia